SEC Form 4 · accession 0000899243-16-022548
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 9, 2016
Accepted (ET)
Jun 13, 2016 · 8:43 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A common stockF1,F2 | Jun 9, 2016 | J | 420,000 | $0.00 | D | 32,864 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 9, 2016, Stapleton Pharma LLC, a Connecticut limited liability company, made a pro rata distribution of 420,000 shares of Class A common stock of Reata Pharmaceuticals, Inc. to its members.
- F2Held of record by Stapleton Pharma LLC. Craig R. Stapleton is the sole managing member of Stapleton Pharma LLC and may be deemed to beneficially own all of the securities held of record by Stapleton Pharma LLC. However, Mr. Stapleton disclaims beneficial ownership of the issuer's securities held of record by Stapleton Pharma LLC except to the extent of his pecuniary interest therein.